However, by reviewing previous prognostic models, we found that these models mainly predict prognosis and survival of all patients with RCC, whereas only few models focus on the clinical response of patients with mRCC receiving VEGF-TKIs as first-line treatment. Here, VEGFA is linked to renal cell carcinoma.